CLDF Title
Contact Us | Bookmark
  HBV   HCC   HCV   HE   NASH   PBC   OTHER
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Featured Programs
      IC-Hep
 
             
  Liver News - REUTERS   Congress Calendar   Physician Resources  
 
 
Screening, brief behavioral counseling can reduce unhealthy alcohol use
11-13-2018
Routine monitoring unneeded for most patients on oral dermatophyte therapy
10-30-2018
Novartis, Pfizer join forces on potentially lucrative fatty liver disease
10-29-2018
HCV core antigen cost-saving alternative for diagnosing hepatitis C
10-26-2018
"Compelling" evidence of link between aspirin use, lower hepatoma risk
10-10-2018
View Complete News Library
 
 
View all Congresses
 
 
 
 
 
 
 
 
 
  Line  
  Featured Abstracts          
 
Factors Associated with Histologic Response in Adult Patients with Nonalcoholic SteatohepatitisL
 
Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States
 
Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
 
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease
 
Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis
 
Towards the elimination of hepatitis B and hepatocellular carcinoma
 
Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care
 
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
 
'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs
 
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis Cin Children Ages 6-11
 
Meeting the Challenge: Hepatitis C Virus and HIV Care Experiences Among HIV Specialty Providers
 
Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation
 
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
 
A Head CT is Unnecessary in the Initial Evaluation of A Cirrhotic Patient with Recurrent Hepatic Encephalopathy
 
 
Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C
 
Evaluating HCV screening, linkage to care, and treatment across insurers
 
Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center
 
Using HIV Surveillance Data for Targeted, Community-based Hepatitis C Virus Testing among Baby Boomers in Washington, D.C
 
Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings
 
The Role of Angiogenesis in Hepatocellular Carcinoma
 
Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
 
Burden of Liver Diseases in the World
 
Targeted and Immune-based Therapies for Hepatocellular Carcinoma
 
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
 
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
 
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study
 
Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening
 
Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma
 
 
Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance
 
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
 
Olfactory Function is Affected in Patients with Cirrhosis Depending on the Severity of Hepatic Encephalopathy
 
Current Management of Hepatic Encephalopathy
 
Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom
 
Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy
 
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
 
Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease
 
Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?
 
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
 
The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options
 
Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
 
 
          View All Abstracts  
  Line  
                               
 
HBV
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
 
HE
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
OTHER
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.